Glucagon-like peptide-1 (GLP-1) compounds have emerged as a compelling therapeutic target for managing metabolic disorders. These naturally occurring molecules are secreted by the gut in response to meal intake, stimulating insulin release and suppressing glucagon secretion. GLP-1 agents demonstrate promising therapeutic outcomes in treating type 2